Scientific poster presented at the 2023 asco annual meeting highlights performance of biocept's cnside™ versus cytology

San diego--(business wire)---- $bioc #cnside--biocept, inc. (nasdaq: bioc) (“biocept” or the “company”), a leading provider of molecular diagnostic assays, products and service, announces a poster presentation at the 2023 american society of clinical oncology (asco) annual meeting underway in chicago showing the ability of cnside™ to detect rates of leptomeningeal metastases (lm) compared with standard csf cytology from lumbar puncture. the poster, titled “evaluating the diagnostic performance of leptomeningeal.
BIOC Ratings Summary
BIOC Quant Ranking